… MacuMira Medical Devices recently introduced the first Health Canada-approved treatment to … date, and a randomised controlled trial published in the International Journal … Canada also approved Eylea’s Aflivu (aflibercept) for the treatment of various …

… to approve its Apitegromab drug for the treatment of patients with … company stated that the FDA raised concerns identified during a … for approval by the European Medicines Agency, and a decision … rule on two of its EYLEA HD Injection regulatory submissions …

… Catalent Indiana’s remediation of the FDA observations, Scholar Rock … review by the European Medicines Agency, and a decision … access. In August, Regeneron Pharmaceuticals Inc. REGN said it … S. Food and Drug Administration (FDA) applications for EYLEA HD (pre- …

… FDA sent a complete response letter (CRL) to the Massachusetts biotech … two more FDA decisions relating to Eylea were being … a potential treatment to pair with obesity drugs. In June … address muscle deterioration. These medicines, all blockbusters, include …

… with Catalent Indiana regarding the FDA’s observations, building up … said on Tuesday. The biotech has not yet provided specific … biotech dropped 12.5% in pre-market trading Tuesday. That the FDA … its high-dose formulation of Eylea have been pushed into the …

… Basel, Switzerland) or Aflibercept (Eylea; Bayer, Basel, Switzerland) … treatment was not consistently documented in the medical records … VEGF drugs in age-related macular degeneration. Pharmaceutics. 2019 … -related macular degeneration trials of faricimab with …

… near term, Bayer’s pharmaceutical unit is banking on … new prostate cancer drug Nubeqa, kidney treatment Kerendia and a … prevention drug Xarelto and an older version of eye medication Eylea. The … Cambridge University, U.S. biotech firm Aspen Neuroscience, and …

… treatment approved by the U.S. Food and Drug Administration (FDA … ) -- Regeneron Pharmaceuticals, Inc. ( … vaccine prior to their enrollment in the PALM clinical trial … biotechnology company that invents, develops and commercializes life-transforming medicines …

… experimental Parkinson’s disease treatment designed to replace dopamine- … needs success in the pharmaceutical sector to overcome past … a trial, though cancer drug Nubeqa and kidney disease medicine Kerendia … well as U.S. biotech company Aspen Neuroscience. Among …

… a biosimilar of aflibercept (Eylea) developed by Alteogen in … the European Union for the treatment of neovascular (wet) age … opinion from the Committee for Medicinal Products for Human Use … In the randomized, controlled trial, 431 patients with wet …